Genmab — Maj 2016

[investor1989]

Topsil bliver solgt !

[investor1989]

Elendig salgspris. Aktiekursen var 0,29 kr. i går og de modtager 0,21 i kontanter og beholder deres usælgelig ejendom i Polen. Jeg mener aktien bør falde ned til de 0,21-0,25 i dag og anbefaler alle der har Topsil at sælge på dette

[Sukkeralf]

Ja frygter også lidt at der er problemer med JNJ372 - meeen sagde Jan ikke at de snart ville begynde rekruteringen med 372 på PI Q&A, da jeg spurgte til det ?

[MUFC_Oberanven]

Jo det sagde han

[MUFC_Oberanven]

Pollux abstract nu Public på EHA: 93% ORR, 43% CR

[investor1989]

OMFG !

[investor1989]

43% CR er vildt. Kan vi se hvornår datacutoff er. De sidste patienter var jo fra maj 2015 så de kan endda måske udvikle sig til flere CR

[Mcjean]

hvor mange sCR?

[Bulder]

Linket er her http://learningcenter.ehaweb.org/eha/2016/21st/135349/meletios.a.dimopoulos.an.open-label.randomised.phase.3.study.of.daratumumab.html?f=p16m3l11456

[Bulder]

Står ikke spec. om sCR. Men 43% CR or better!

[gentogen]

Drømmer jeg eller er jeg vågen.

[OHW]

The combination of D and Rd potentially represents a new standard of care for pts with >1 prior treatment. :-))

[gentogen]

doubling stringent CR/CR rates

[OHW]

Man tør næsten ikke drømme om potentialet..

[Fantomas]

Dara kommer til at sende hematology læger på pension..

[Sukkeralf]

Heftige data - nogen der har Elotuzumab data ved hånden ?

[gentogen]

OFC is a rapidly acting combination, inducing high response rates, including deep and durable responses in heavily pretreated WM patients, even in those refractory to rituximab and/or bortezomib. Ofatumumab is well tolerated

[Bulder]

Elo: The co-primary endpoints of this study, progression-free survival (PFS) as assessed by hazard ratio (HR) and overall response rate (ORR), were achieved, with extended follow-up data showing a 53% relative improvement in PFS rate at three years (23% versus 15%). Additionally, a pre-specified interim analysis for overall survival (OS) found a positive trend favoring the Empliciti combination versus Rd alone (HR=0.77 [95% CI: 0.61, 0.97, p=0.0257])

[Sukkeralf]

Among the patients treated with Empliciti, Revlimid, and dex­a­meth­a­sone, 79 percent achieved at least a partial response to treatment, compared to 66 percent of the patients who received Revlimid and dex­a­meth­a­sone alone

[Bulder]

Mere elo: he ERd regimen demonstrated a significant improvement in ORR of 78.5% (95% CI: 73.6-82.9; p=0.0002) versus 65.5% in the Rd arm (95% CI: 60.1-70.7).